ACADIA PHARMACEUTICALS INC. Operating Lease Cost
ACADIA PHARMACEUTICALS INC. (ACAD) reported Operating Lease Cost of $5.06 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-08-05
- ACADIA PHARMACEUTICALS INC. operating lease, cost for the quarter ending 2026-06-30 was $5.06M, a 30.78% increase year-over-year.
- ACADIA PHARMACEUTICALS INC. operating lease, cost for the quarter ending 2026-03-31 was $4.15M, a 2.75% increase year-over-year.
- ACADIA PHARMACEUTICALS INC. operating lease, cost for the quarter ending 2025-12-31 was $3.54M, a 0.06% decline year-over-year.
- ACADIA PHARMACEUTICALS INC. operating lease, cost for the quarter ending 2025-09-30 was $3.53M, a 32.94% increase year-over-year.
- ACADIA PHARMACEUTICALS INC. operating lease, cost for fiscal 2025 was $14.98M, a 26.56% increase from fiscal 2024.
- ACADIA PHARMACEUTICALS INC. operating lease, cost for fiscal 2024 was $11.84M, a 14.43% increase from fiscal 2023.
- ACADIA PHARMACEUTICALS INC. operating lease, cost for fiscal 2023 was $10.34M, a 27.77% increase from fiscal 2022.
- ACADIA PHARMACEUTICALS INC. operating lease, cost for fiscal 2022 was $8.10M, a 8.78% decline from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 3 month as first filed | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $5.06M 10-Q · filed 2026-08-05 | $9.21M 10-Q · filed 2026-08-05 | $12.75M derived: sum of 3 quarters · filed 2026-08-05 | $16.28M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2026-03-31 | $4.15M 10-Q · filed 2026-05-07 | $7.69M derived: sum of 2 quarters · filed 2026-05-07 | $11.22M derived: sum of 3 quarters · filed 2026-05-07 | $15.09M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-12-31 | $3.54M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $7.07M derived: sum of 2 quarters · filed 2026-02-26 | $10.94M derived: sum of 3 quarters · filed 2026-08-05 | $14.98M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $3.53M 10-Q · filed 2025-11-06 | $7.40M derived: sum of 2 quarters · filed 2026-08-05 | $11.44M 10-Q · filed 2025-11-06 | $14.98M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-06-30 | $3.87M 10-Q · filed 2026-08-05 | $7.91M 10-Q · filed 2026-08-05 | $11.45M derived: sum of 3 quarters · filed 2026-08-05 | $14.11M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-03-31 | $4.04M 10-Q · filed 2026-05-07 | $7.58M derived: sum of 2 quarters · filed 2026-05-07 | $10.24M derived: sum of 3 quarters · filed 2026-05-07 | $13.06M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | $3.54M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $6.20M derived: sum of 2 quarters · filed 2026-02-26 | $9.03M derived: sum of 3 quarters · filed 2026-02-26 | $11.84M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $2.66M 10-Q · filed 2025-11-06 | $5.48M derived: sum of 2 quarters · filed 2025-11-06 | $8.29M 10-Q · filed 2025-11-06 | $11.01M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-06-30 | $2.83M 10-Q · filed 2025-08-07 | $5.64M 10-Q · filed 2025-08-07 | $8.35M derived: sum of 3 quarters · filed 2026-02-26 | $11.06M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-03-31 | $2.81M 10-Q · filed 2025-05-08 | $5.53M derived: sum of 2 quarters · filed 2026-02-26 | $8.23M derived: sum of 3 quarters · filed 2026-02-26 | $10.97M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2023-12-31 | $2.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $5.42M derived: sum of 2 quarters · filed 2026-02-26 | $8.16M derived: sum of 3 quarters · filed 2026-02-26 | $10.34M 10-K · filed 2026-02-26 | |
| 2023-09-30 | $2.71M 10-Q · filed 2024-11-07 | $5.45M derived: sum of 2 quarters · filed 2024-11-07 | $7.63M 10-Q · filed 2024-11-07 | $9.75M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-06-30 | $2.74M 10-Q · filed 2024-08-07 | $4.92M 10-Q · filed 2024-08-07 | $7.04M derived: sum of 3 quarters · filed 2025-02-27 | $9.17M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-03-31 | $2.18M 10-Q · filed 2024-05-09 | $4.30M derived: sum of 2 quarters · filed 2025-02-27 | $6.43M derived: sum of 3 quarters · filed 2025-02-27 | $8.16M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2022-12-31 | $2.12M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $4.25M derived: sum of 2 quarters · filed 2025-02-27 | $5.98M derived: sum of 3 quarters · filed 2025-02-27 | $8.10M 10-K · filed 2025-02-27 | |
| 2022-09-30 | $2.13M 10-Q · filed 2023-11-03 | $3.87M derived: sum of 2 quarters · filed 2023-11-03 | $5.98M 10-Q · filed 2023-11-03 | $7.83M derived: sum of 4 quarters · filed 2024-02-28 | |
| 2022-06-30 | $1.74M 10-Q · filed 2023-08-03 | $3.85M 10-Q · filed 2023-08-03 | $5.71M derived: sum of 3 quarters · filed 2024-02-28 | $7.72M derived: sum of 4 quarters · filed 2024-02-28 | |
| 2022-03-31 | $2.11M 10-Q · filed 2023-05-08 | $3.97M derived: sum of 2 quarters · filed 2024-02-28 | $5.98M derived: sum of 3 quarters · filed 2024-02-28 | $8.61M derived: sum of 4 quarters · filed 2024-02-28 | |
| 2021-12-31 | $1.86M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $3.87M derived: sum of 2 quarters · filed 2024-02-28 | $6.50M derived: sum of 3 quarters · filed 2024-02-28 | $8.87M 10-K · filed 2024-02-28 | |
| 2021-09-30 | $2.01M 10-Q · filed 2022-11-03 | $4.64M derived: sum of 2 quarters · filed 2022-11-03 | $7.02M 10-Q · filed 2022-11-03 | $9.18M derived: sum of 4 quarters · filed 2023-02-28 | |
| 2021-06-30 | $2.62M 10-Q · filed 2022-08-09 | $5.00M 10-Q · filed 2022-08-09 | $7.17M derived: sum of 3 quarters · filed 2023-02-28 | $9.00M derived: sum of 4 quarters · filed 2023-02-28 | |
| 2021-03-31 | $2.38M 10-Q · filed 2022-05-05 | $4.54M derived: sum of 2 quarters · filed 2023-02-28 | $6.38M derived: sum of 3 quarters · filed 2023-02-28 | $7.81M derived: sum of 4 quarters · filed 2023-02-28 | |
| 2020-12-31 | $2.17M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $4.00M derived: sum of 2 quarters · filed 2023-02-28 | $5.43M derived: sum of 3 quarters · filed 2023-02-28 | $6.92M 10-K · filed 2023-02-28 | |
| 2020-09-30 | $1.83M 10-Q · filed 2021-11-09 | $3.26M derived: sum of 2 quarters · filed 2021-11-09 | $4.75M 10-Q · filed 2021-11-09 | $6.06M derived: sum of 4 quarters · filed 2022-03-01 | |
| 2020-06-30 | $1.43M 10-Q · filed 2021-08-05 | $2.92M 10-Q · filed 2021-08-05 | $4.23M derived: sum of 3 quarters · filed 2022-03-01 | $5.52M derived: sum of 4 quarters · filed 2022-03-01 | |
| 2020-03-31 | $1.49M 10-Q · filed 2021-05-06 | $2.80M derived: sum of 2 quarters · filed 2022-03-01 | $4.10M derived: sum of 3 quarters · filed 2022-03-01 | $5.37M derived: sum of 4 quarters · filed 2022-03-01 | |
| 2019-12-31 | $1.31M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $2.61M derived: sum of 2 quarters · filed 2022-03-01 | $3.88M derived: sum of 3 quarters · filed 2022-03-01 | $5.16M 10-K · filed 2022-03-01 | |
| 2019-09-30 | $1.30M 10-Q · filed 2020-11-04 | $2.57M derived: sum of 2 quarters · filed 2020-11-04 | $3.84M 10-Q · filed 2020-11-04 | $5.03M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2019-06-30 | $1.27M 10-Q · filed 2020-08-06 | $2.55M 10-Q · filed 2020-08-06 | $3.73M derived: sum of 3 quarters · filed 2021-02-25 | $4.88M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2019-03-31 | $1.27M 10-Q · filed 2020-05-08 | $1.30M 10-Q · filed 2019-05-02 | $2.46M derived: sum of 2 quarters · filed 2021-02-25 | $3.61M derived: sum of 3 quarters · filed 2021-02-25 | $4.78M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $1.18M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $2.33M derived: sum of 2 quarters · filed 2021-02-25 | $3.50M derived: sum of 3 quarters · filed 2021-02-25 | $4.50M 10-K · filed 2021-02-25 | |
| 2018-09-30 | $1.15M 10-Q · filed 2019-10-31 | $2.32M derived: sum of 2 quarters · filed 2019-10-31 | $3.32M 10-Q · filed 2019-10-31 | ||
| 2018-06-30 | $1.17M 10-Q · filed 2019-08-01 | $2.17M 10-Q · filed 2019-08-01 | |||
| 2018-03-31 | $1.00M 10-Q · filed 2019-05-02 | ||||
| 2017-12-31 | $3.83M 10-K · filed 2020-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |